UW-CTRI Triple Medication Smoking Cessation Study

Phase 4 Completed 36 enrolled University of Wisconsin, Madison

NaSingle-groupOpen-labelTreatment

Summary

This study will focus on enhancing future smoking cessation treatment effectiveness by piloting a potentially more powerful combination of three FDA-approved pharmacotherapies: varenicline plus combination of two types of nicotine replacement therapy (NRT) treatment (nicotine lozenge and nicotine patch). Data from this pilot study will help inform the design of future studies that would use this combination treatment as a cessation tool within the chronic care arsenal of treatments.

Timeline

Start: 2016-02
Primary completion: 2016-06-13
Completion: 2016-06-13

Publications

Berg KM, Jorenby DE, Baker TB, Fiore MC. Triple Smoking Cessation Therapy with Varenicline, Nicotine Patch and Nicotine Lozenge: A Pilot Study to Assess Tolerability, Satisfaction, and End-of-Treatment Quit Rates. J Smok Cessat. 2018 Sep;13(3):145-153. doi: 10.1017/jsc.2017.18. Epub 2017 Sep 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nicotine Mini	Unknown	—	—
Subject	Nicotine Transdermal Patch	Unknown	—	Other
Subject	Varenicline	Small molecule	—	—

Indications

No indication recorded.